Is GLP-1 Safe Long-Term? What 5 Years of Data Shows

When a medication produces the kind of weight-loss results we see with semaglutide and tirzepatide, scepticism is warranted. Patients and clinicians rightly ask: what happens if you take this for five, ten, or twenty years? Are there risks that the short trials simply could not detect?

The honest answer is that we have more long-term data than the headlines suggest, and it paints a broadly reassuring picture, with a few genuinely open questions. This article works through what the evidence actually shows, where the gaps remain, and how the MHRA monitors ongoing safety in the UK.

How Long Has the Data Been Accumulating?

Semaglutide was first approved for type 2 diabetes management in the UK in 2019 (as Ozempic). Liraglutide, the predecessor GLP-1 receptor agonist, has been in clinical use since 2009, giving us over fifteen years of real-world pharmacovigilance data on this drug class.

The STEP trial programme, which underpinned Wegovy's approval for weight management, ran for 68 weeks in its primary phase. STEP 4 extended treatment and demonstrated that weight regain occurs rapidly on stopping, which itself informs long-term use decisions. Meanwhile, the SELECT cardiovascular outcomes trial followed patients for a median of 34 months.

That is not a lifetime of data. But for a drug class, five-plus years of post-marketing surveillance across millions of prescriptions is a meaningful signal.

The Thyroid Question

The most frequently cited concern is thyroid cancer. In rodent studies, semaglutide and liraglutide caused dose-dependent increases in thyroid C-cell tumours. This is why the prescribing information carries a specific warning, and why GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2).

The critical context: C-cells in rodents express GLP-1 receptors at far higher density than in humans. Human thyroid C-cells have very low GLP-1 receptor expression, which is the biological basis for cautious optimism that the rodent finding does not translate directly.

The MHRA continues to monitor thyroid signals through its Yellow Card pharmacovigilance system. To date, no confirmed causal link between GLP-1 receptor agonists and thyroid cancer in humans has been established. If you have a personal or family history of thyroid disease, discuss this specifically with your prescriber before starting.

Pancreatitis: Signal or Noise?

Pancreatitis appeared as a theoretical concern because GLP-1 receptors are expressed in pancreatic tissue, and early case reports raised the possibility. Regulatory agencies required large cardiovascular outcome trials to capture this signal prospectively.

Current guidance from the MHRA does not identify pancreatitis as a confirmed class effect of GLP-1 medications. Patients with a history of pancreatitis are typically excluded from treatment, and unexplained severe abdominal pain should be investigated promptly, but population-level data does not support routine avoidance in patients without prior pancreatitis.

Cardiovascular Safety: Where the Data Is Strongest

This is where the long-term evidence is most compelling, and it genuinely shifts the risk-benefit calculation for patients at elevated cardiovascular risk.

SELECT is particularly important because it enrolled people without diabetes, directly addressing whether cardiovascular benefit is mediated through glucose control or through other mechanisms (weight reduction, inflammation, direct cardiac effects). The 20% MACE reduction occurred across all subgroups and was not explained by weight loss alone.

For UK patients with a BMI over 27 and established cardiovascular disease, SELECT provides the strongest long-term outcome data in the class. This is why the NICE appraisal of Wegovy for cardiovascular risk reduction in this specific population was positive.

Read more about the cardiovascular evidence in our detailed cardiovascular benefits guide.

Muscle Mass: An Emerging Consideration

One area receiving increasing clinical attention is lean mass loss during GLP-1-driven weight reduction. Rapid weight loss through any mechanism can reduce skeletal muscle mass, which has implications for long-term functional health, particularly in older patients.

This does not mean GLP-1 medications are contraindicated in older adults, the metabolic and cardiovascular benefits often outweigh this concern, but it does reinforce the clinical guidance that resistance exercise and adequate protein intake should accompany treatment. Long-term bone density data is still accumulating.

Gallbladder Disease

Rapid weight loss from any cause increases gallstone risk, and GLP-1 medications are no exception. Clinical trials have documented increased rates of gallbladder-related events (cholelithiasis, cholecystitis) compared with placebo, particularly with higher-dose semaglutide.

This is a known, documented risk listed in the prescribing information. Patients experiencing right upper quadrant pain, especially after fatty meals, should seek medical attention. For most patients, the overall benefit-risk balance remains favourable, but this is worth discussing with your prescriber if you have a history of gallstones.

What the MHRA Is Watching

The UK's Medicines and Healthcare products Regulatory Agency runs continuous post-marketing surveillance. Key signals actively monitored include:

• Gastroparesis (delayed gastric emptying), cases of severe, persistent gastric slowing have been reported and are under review
• Intestinal obstruction, rare but reported, particularly in patients with prior abdominal surgery
• Suicidal ideation, a precautionary signal under review; current evidence does not establish causality
• Thyroid outcomes, ongoing pharmacovigilance

The Yellow Card reporting system allows UK patients and clinicians to report suspected adverse reactions directly. If you experience any unexpected symptoms on a GLP-1 medication, reporting through Yellow Card contributes to the evidence base.

What the STEP Trial Extensions Show

The two-year STEP 5 data is meaningful because it demonstrates that the drug class does not appear to generate new or accumulating toxicity with prolonged use. The adverse event profile at 104 weeks was consistent with what was seen in the first 68 weeks, dominated by gastrointestinal side effects that tend to reduce over time.

What We Genuinely Do Not Yet Know

Intellectual honesty requires acknowledging the real gaps:

Effects beyond five years, The longest continuous trial data we have for weight-management doses runs to approximately two years. Post-marketing surveillance supplements this, but five-to-ten-year prospective outcome data for the higher-dose formulations does not yet exist.

Lifetime use, GLP-1 medications are increasingly framed as chronic disease treatments requiring indefinite continuation. What indefinite actually means in terms of safety remains genuinely unknown.

Rare adverse events, Events with an incidence below 1 in 10,000 require enormous datasets to detect reliably. Some rare risks may not become apparent for another decade.

Paediatric long-term effects, Semaglutide is being studied in adolescents. Long-term developmental data in this group is sparse.

Questions to Ask Your Prescriber

Before committing to long-term GLP-1 treatment, a reasonable conversation with your prescriber should cover:

• Your personal cardiovascular risk profile and whether SELECT data applies to you
• Any personal or family history of thyroid disease or MEN2
• A plan for monitoring (see our GLP-1 monitoring protocol)
• Gallbladder symptoms and what to watch for
• Resistance exercise and protein intake during treatment
• The plan if you need to stop, and what managing weight without the medication looks like

Related Reading

• Understanding GLP-1 Side Effects
• GLP-1 Cardiovascular Benefits
• GLP-1 Monitoring Protocol for UK Patients